Efficacy and Safety of Basiliximab Versus Daclizumab in Kidney Transplantation: A Meta-Analysis.
Transplant Proc
; 47(8): 2439-45, 2015 Oct.
Article
en En
| MEDLINE
| ID: mdl-26518947
ABSTRACT
BACKGROUND:
Interleukin-2 receptor antagonists (IL-2RAs) have been extensively used in kidney transplant patients to prevent the occurrence of acute rejection. The efficacy and safety of basiliximab and daclizumab, the 2 most commonly used IL-2RAs in clinics, have been compared in a number of randomized controlled trials, but no definite conclusions have been drawn.OBJECTIVE:
This meta-analysis aimed to compare the efficacy and safety of basiliximab and daclizumab in kidney transplant patients.METHODS:
We performed keyword searches in Pubmed, Embase, and the Cochrane library. In total, 6 randomized controlled trials with 509 patients were included in this meta-analysis. Data collected included patient survival, graft survival, acute rejection, infection, and cytomegalovirus infection. The outcome measure was the relative risk of basiliximab versus daclizumab.RESULTS:
Therapy with basiliximab and daclizumab resulted in similar outcomes regarding acute rejection (6-month 95% confidence interval [CI], 0.09-1.14; 12-month 95% CI, 0.53-1.91), patient survival (95% CI, 0.97-1.04), graft survival (95% CI, 0.98-1.08), infection (95% CI, 0.66-1.01), and cytomegalovirus infection (95% CI, 0.45-1.14) within the follow-up period. There were no significant differences in safety and efficacy between the 2 drugs.CONCLUSIONS:
The safety and efficacy of daclizumab and basiliximab are similar in kidney transplant recipients.
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Proteínas Recombinantes de Fusión
/
Inmunoglobulina G
/
Trasplante de Riñón
/
Anticuerpos Monoclonales Humanizados
/
Rechazo de Injerto
/
Inmunosupresores
/
Anticuerpos Monoclonales
Tipo de estudio:
Clinical_trials
/
Etiology_studies
/
Systematic_reviews
Límite:
Humans
Idioma:
En
Año:
2015
Tipo del documento:
Article